Compare QDEL & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | JANX |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 989.5M | 975.7M |
| IPO Year | 2022 | 2021 |
| Metric | QDEL | JANX |
|---|---|---|
| Price | $11.89 | $17.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $28.25 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 1.2M | 781.8K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,730,200,000.00 | $10,000,000.00 |
| Revenue This Year | $3.51 | N/A |
| Revenue Next Year | $3.86 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.92 | $12.12 |
| 52 Week High | $35.58 | $35.34 |
| Indicator | QDEL | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 33.35 | 48.13 |
| Support Level | $11.37 | $13.09 |
| Resistance Level | $12.85 | $19.14 |
| Average True Range (ATR) | 0.75 | 0.81 |
| MACD | -0.18 | -0.05 |
| Stochastic Oscillator | 5.63 | 16.45 |
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.